BDX
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. The company serves healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Its operations are organized into three main segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical provides medication delivery solutions, medication management systems, pharmaceutical systems, and advanced patient monitoring technologies. BD Life Sciences offers diagnostic solutions for infectious diseases and cancers, biosciences tools for cell analysis, and specimen management systems. BD Interventional supplies vascular, urology, oncology, and surgical specialty products. In 2024, the company acquired Edwards Lifesciences’ Critical Care product group, which was renamed BD Advanced Patient Monitoring. In 2025, BD agreed to combine its Biosciences and Diagnostic Solutions business with Waters Corporation. The company was incorporated in 1906 as a successor to a business started in 1897.

Summarised from the company's own disclosures, fiscal year ended Nov 2025

Industry Medical Devices Homepage bd.com
Sector Healthcare IR page investors.bd.com
Tags
medical devices, diagnostics, medication delivery, vascular access, infection prevention, cell analysis, specimen management, surgical products, urology, oncology, patient monitoring, pharmaceutical systems, BD Medical, BD Life Sciences, BD Interventional, BD Advanced Patient Monitoring, BD Surgiphor, BD ChloraPrep, Waters Corporation
Press page —

Metrics

Valuation  
Market cap $ 57.201B
Market cap (USD) $ 57.201B
P/E 36.08
PEG 41.52
P/BV 2.34
P/S 2.74
P/OCF 16.68
P/FCF 21.42
Dividend yield <0.01%
Turnover / mcap —
Returns  
ROE 6.5%
ROI 3.8%
ROIC 5.2%
Profit margin 7.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 0.87%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 68.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 33
Quality score -5.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Revenue 21.84B 20.178B 19.372B 18.87B 20.248B 17.117B 17.29B 15.983B 12.093B 12.483B 10.282B 8.446B 8.054B 7.708B 7.829B 7.372B 7.161B 7.156B 6.36B 5.835B 5.415B 4.935B 4.528B 4.033B 3.754B — —
Net profit 1.678B 1.705B 1.484B 1.779B 2.092B 874M 1.233B 311M 1.1B 976M 695M 1.185B 1.293B 1.17B 1.271B 1.318B 1.232B 1.127B 890.033M 752.28M 722.263M 467.402M 547.056M 479.982M 401.652M 392.897M 275.719M
Free cash flow 2.67B 3.119B 2.116B 1.498B 3.416B 2.729B 2.373B 1.97B 1.823B 1.866B 1.134B 1.154B 1.195B 1.206B 1.197B 1.122B 1.1B -602.88M -552.006M -459.308M 906.301M 834.542M 644.657M 576.33M 407.891M 239.121M 120.245M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Share price 187.17 241.1 258.53 222.83 245.82 232.68 252.96 261 195.95 179.73 132.66 113.81 100.02 78.56 73.32 74.1 69.75 80.26 78.18 60.9 — — — — — — —
Price performance 12m -0.22 -0.07 0.16 -0.09 0.06 -0.08 -0.03 0.33 0.09 0.35 0.17 0.14 0.27 0.07 -0.01 0.06 -0.13 0.03 0.28 — — — — — — — —

Filed figures

Figure Sep 2016 Sep 2017 Sep 2018 Sep 2019 Sep 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025
Balance sheet detail
Trade receivables (USD) 1.62B 1.74B 2.32B 2.35B 2.4B 2.5B 2.19B 2.53B 3.03B 2.99B
↳ YoY growth 0% +7.8% +33.0% +1.1% +2.3% +4.1% -12.3% +15.7% +19.7% -1.3%
↳ 5y CAGR +5.7% +6.9% +13.3% +14.6% +8.2% +9.1% +4.7% +1.8% +5.3% +4.5%
Borrowings, current (USD) 1B 203M 2.6B 1.31B 707M 500M 2.18B 1.14B 2.17B 1.56B
Borrowings, non-current (USD) 10.6B 18.7B 18.9B 18.1B 17.2B 17.1B 13.9B 14.7B 17.9B 17.6B
Lease liabilities (USD) — — — — 442M 470M 502M 531M 809M 839M
Cash and deposits (USD) 1.54B 14.2B 1.14B 536M 2.83B 2.28B 1.01B 1.42B 1.72B 641M
Intangible assets (USD) — — — — 13.8B 12.7B 12.3B 10.9B 10.9B 9.39B
Right-of-use assets (USD) — — — — 418M 446M 482M 517M 876M 885M
Net debt (borrowings + leases - cash) (USD) 10B 4.69B 20.4B 18.9B 15.5B 15.8B 15.6B 15B 19.2B 19.4B
Cash flow detail
Operating cash flow (USD) 2.56B 2.55B 2.87B 3.33B 3.54B 4.65B 2.47B 2.99B 3.84B 3.43B
Purchases of property, plant and equipment (USD) -693M -727M -895M -957M -810M -1.23B -973M -874M -725M -760M
Purchases of intangible assets (USD) -25M — — — — — — — — —
Change in inventories (cash effect) (USD) 69M -46M 246M -149M -125M -104M -631M -15M 98M -410M
Change in payables (cash effect) (USD) 368M 134M 867M -470M 205M 687M -473M -517M 625M -185M
Dividends paid (cash effect) (USD) -562M -677M -927M -984M -1.03B -1.05B -1.08B -1.11B -1.1B -1.2B
Share buybacks (cash effect) (USD) 0.00 -220M 0.00 0.00 0.00 -1.75B -500M 0.00 -500M -1B
Interest paid (cash effect) (USD) -392M -435M -674M -658M -515M -474M -390M -452M -473M -628M
Income taxes paid (cash effect) (USD) -218M -265M -235M -536M -518M -670M -532M -629M -653M -599M
Share-based compensation (USD) 196M 174M 322M 261M 244M 237M 233M 259M 247M 258M
Free cash flow (OCF - PPE - intangibles) (USD) 1.84B 1.82B 1.97B 2.37B 2.73B 3.42B 1.5B 2.12B 3.12B 2.67B
Income detail
Research and development expense (USD) 828M 774M 1.01B 1.06B 1.1B 1.34B 1.26B 1.24B 1.19B 1.27B
↳ 5y CAGR +11.7% +10.4% +15.3% +14.1% +11.6% +10.1% +10.2% +4.2% +2.3% +2.9%
Total comprehensive income (USD) 786M 1.31B 125M 859M 609M 2.55B 2.38B 1.42B 1.52B 1.52B
Comprehensive income to owners (USD) 786M 1.31B 125M 859M 609M 2.55B 2.38B 1.42B 1.52B 1.52B
Reported Nov 23, 2016 Nov 22, 2017 Nov 21, 2018 Nov 27, 2019 Nov 24, 2021 Nov 24, 2021 Nov 22, 2022 Nov 21, 2023 Nov 27, 2024 Nov 25, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Franklin Lakes, NJ 07417 Bull 5 Bear 0 Results

www.bd.com

Contacts:

Investors: Shawn Bevec, SVP, Investor Relations - [email protected]

Media: Matt Marcus, VP, Public Relations - [email protected]

BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results

•Q4 revenue of $5.3 billion increased 5.4% as reported, 5.6% FXN

•Q4 GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively

•FY26 revenue of $19.5 billion increased 4.9% as reported, 3.9% FXN

•FY26 GAAP and adjusted diluted EPS of $5.06 and $12.70, respectively

•FY26 cash from continuing operations increased 30.0% to $3.6 billion and free cash flow increased 42.5% to $2.9 billion

•Company issues FY27 guidance

FRANKLIN LAKES, NJ (November 5, 2026) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 fourth quarter and full year, which ended September 30, 2026.

"We delivered a strong fourth quarter, with 5.6% revenue growth and broad-based performance led by our key growth platforms," said Tom Polen, chairman, CEO and president of BD.

Franklin Lakes, NJ 07417 Bull 5 Bear 0 Results

www.bd.com

Contacts:

Investors: Shawn Bevec, SVP, Investor Relations - [email protected]

Media: Matt Marcus, VP, Public Relations - [email protected]

BD Reports Third Quarter Fiscal 2026 Financial Results

•Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXN

•GAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectively

•Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion

•Company updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidance

FRANKLIN LAKES, NJ (August 6, 2026) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026.

"We delivered a strong third quarter, with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations," said Tom Polen, chairman, CEO and president of BD.

Mike Garrison to Retire from BD Bull 0 Bear 0 Management

FRANKLIN LAKES, N.J. (July 22, 2026) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2.

Garrison is currently executive vice president and president of the Medical Essentials and BioPharma Systems segments at BD. During his tenure, Garrison held several leadership roles including executive vice president and president of BD’s Medical segment, worldwide president of Medication Management Solutions and worldwide president of Surgery. Prior to joining BD in 2005, Garrison held various roles across R&D and marketing within the MedTech industry.

"Mike has made a significant impact on BD over the past two decades, helping guide our company through periods of transformation while always keeping our customers, patients and associates at the center of his decisions," said Tom Polen, Chairman, CEO and President of BD. "He has built strong teams, developed exceptional leaders and helped position our business for the future.

Prompts

Becton, Dickinson and Company (ticker BDX), listed in United States.

ETFs Holding Becton, Dickinson and Company

ETF Weight in ETF Shares Market value As of
LBAY 3.48% 2,798 $ 605.683K Nov 17, 2026
FLV 3.07% 62,193 $ 11.699M Aug 31, 2026
DIVP 3.04% 10,908 $ 1.651M Jun 30, 2026
FEGE 2.77% 369,805 $ 69.564M Aug 31, 2026
FPAG 2.70% 96,460 $ 14.597M Jun 30, 2026
BUSA 2.53% 49,807 $ 7.537M Jun 30, 2026
BASV 2.37% 64,053 $ 9.693M Jun 30, 2026
MBOX 2.37% 16,898 $ 3.64M Nov 18, 2026
EQTY 2.14% 184,537 $ 30.563M Jul 31, 2026
YLDE 2.03% 21,624 $ 3.272M Jun 30, 2026
SWP 2.02% 16,080 $ 3.025M Aug 31, 2026
MMID 1.62% 3,123 $ 587.468K Aug 31, 2026
LCF 1.51% 6,475 $ 979.862K Jun 30, 2026
LOPP 1.50% 1,620 $ 245.155K Jun 30, 2026
TCAL 1.43% 21,860 $ 4.732M Nov 17, 2026
MKTN short -1.34% -9,492 $ -1.436M Jun 30, 2026
DVND 1.25% 4,365 $ 660.555K Jun 30, 2026
CSTK 1.20% 12,721 $ 2.107M Jul 31, 2026
TCAF 1.20% 594,914 $ 128.781M Nov 17, 2026
ITAN 1.07% 6,142 $ 1.323M Nov 17, 2026
AIVL 1.04% 28,532 $ 4.318M Jun 30, 2026
RGEF 0.96% 34,404 $ 7.447M Nov 17, 2026
REMC 0.95% 213 $ 32.233K Jun 30, 2026
PVAL 0.89% 667,036 $ 125.476M Aug 31, 2026
ACVU 0.87% 11,240 $ 0.00 Nov 18, 2026
WBIG 0.80% 1,453 $ 219.882K Jun 30, 2026
TMED 0.72% 1,098 $ 166.16K Jun 30, 2026
JAVA 0.59% 204,368 $ 44.025M Nov 17, 2026
AVMC 0.50% 12,735 $ 2.757M Nov 16, 2026
PAPI 0.50% 13,084 $ 1.98M Jun 30, 2026
VFMV 0.43% 10,309 $ 1.939M Aug 31, 2026
VFVA 0.37% 18,654 $ 3.509M Aug 31, 2026
GVLU 0.36% 4,383 $ 948.788K Nov 17, 2026
DFLV 0.33% 118,320 $ 25.523M Nov 12, 2026
PEPS 0.29% 558 $ 84.442K Jun 30, 2026
INRO 0.28% 7,544 $ 1.633M Nov 16, 2026
DFUV 0.24% 175,395 $ 37.834M Nov 12, 2026
FLSP 0.24% 14,925 $ 2.259M Jun 30, 2026
NQLT 0.23% 591 $ 111.173K Aug 31, 2026
GMOV 0.22% 1,254 $ 235.89K Aug 31, 2026
IALT 0.22% 79,255 $ 17.156M Nov 16, 2026
GSPY 0.22% 6,960 $ 1.507M Nov 17, 2026
FTLS 0.20% 23,541 $ 0.00 Nov 16, 2026
CAPE 0.20% 3,099 $ 468.972K Jun 30, 2026
GEW 0.18% 1,348 $ 253.572K Aug 31, 2026
FEMV 0.18% 63 $ 9,533.79 Jun 30, 2026
MSLC 0.18% 38,778 $ 7.295M Aug 31, 2026
SHRT 0.16% 98 $ 21.214K Nov 17, 2026
DFVX 0.15% 3,990 $ 860.683K Nov 12, 2026
XMAG 0.14% 1,353 $ 291.856K Nov 13, 2026
JEPI 0.13% 268,409 $ 57.821M Nov 17, 2026
AAUS 0.13% 3,138 $ 680K Nov 18, 2026
LCTU 0.12% 6,206 $ 1.343M Nov 16, 2026
DXUV 0.11% 32,731 $ 7.06M Nov 12, 2026
DFAC 0.11% 453,206 $ 97.761M Nov 12, 2026
DFAU 0.11% 64,200 $ 13.849M Nov 12, 2026
JUSA 0.09% 3,726 $ 802.655K Nov 17, 2026
LGDX 0.09% 574 $ 124.254K Nov 17, 2026
MODL 0.09% 6,077 $ 919.632K Jun 30, 2026
DFUS 0.09% 89,132 $ 19.227M Nov 12, 2026
ACVF 0.09% 795 $ 131.668K Jul 31, 2026
TACU 0.09% 73 $ 15.802K Nov 17, 2026
DFSU 0.09% 9,465 $ 2.042M Nov 12, 2026
IQSZ 0.08% 858 $ 142.102K Jul 31, 2026
DCOR 0.07% 147,547 $ 31.827M Nov 12, 2026
NTSD 0.07% 165 $ 24.969K Jun 30, 2026
JFLI 0.07% 165 $ 35.544K Nov 17, 2026
YOKE 0.07% 748 $ 160K Nov 18, 2026
VOXP 0.07% 24 $ 3,974.88 Jul 31, 2026
GDE 0.07% 1,720 $ 323.549K Aug 31, 2026
HCMT 0.06% 1,923 $ 318.487K Jul 31, 2026
CORO 0.05% 40,208 $ 7.711M Nov 16, 2026
NTSX 0.05% 4,467 $ 675.991K Jun 30, 2026
APUE 0.05% 6,347 $ 1.194M Aug 31, 2026
AVLC 0.04% 2,876 $ 622.568K Nov 16, 2026
CSHP 0.03% 560 $ 121.223K Nov 16, 2026
AVSU 0.03% 666 $ 144.169K Nov 16, 2026
EBI 0.01% 213 $ 40.067K Aug 31, 2026
NPFE 0.00% 9 $ 1,490.58 Jul 31, 2026
AVUS 0.00% 1,498 $ 324.272K Nov 16, 2026